{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T04:09:43Z","timestamp":1777867783968,"version":"3.51.4"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2026,2,7]],"date-time":"2026-02-07T00:00:00Z","timestamp":1770422400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,2,7]],"date-time":"2026-02-07T00:00:00Z","timestamp":1770422400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"Funding This work was supported by Chia Tai Tianqing Pharmaceutical Group Co.,Ltd, Jiangsu, China,","award":["funding number: phase I 2019-004"],"award-info":[{"award-number":["funding number: phase I 2019-004"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Drug Investig"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1007\/s40261-026-01528-0","type":"journal-article","created":{"date-parts":[[2026,2,7]],"date-time":"2026-02-07T06:29:44Z","timestamp":1770445784000},"page":"321-330","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["A Single-Center, Randomized, Open-Label, Two-Formulation, Two-Sequence, Two-Period Crossover Study to Evaluate the Bioequivalence of Two Eltrombopag Olamine Tablets (25 mg) in Healthy Chinese Subjects in the Fed State"],"prefix":"10.1007","volume":"46","clinical-trial-number":[{"clinical-trial-number":"nct06768619","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Keyi","family":"Wu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qin","family":"Ren","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yanli","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yannan","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhengzhi","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yang","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qiaohuan","family":"Deng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yingzi","family":"Cui","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2863-6516","authenticated-orcid":false,"given":"Haimiao","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,2,7]]},"reference":[{"issue":"4","key":"1528_CR1","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000024436","volume":"100","author":"QL Zhu","year":"2021","unstructured":"Zhu QL, Wu W. Comparison of clinical efficacy of laparoscopic splenectomy versus open splenectomy for idiopathic thrombocytopenic purpura: a meta-analysis. Medicine (Baltimore). 2021;100(4):e24436. https:\/\/doi.org\/10.1097\/MD.0000000000024436.","journal-title":"Medicine (Baltimore)"},{"key":"1528_CR2","doi-asserted-by":"publisher","DOI":"10.1155\/2017\/9529752","volume":"2017","author":"K Sheema","year":"2017","unstructured":"Sheema K, Ikramdin U, Arshi N, Farah N, Imran S. Role of Helicobacter pylori eradication therapy on platelet recovery in chronic immune thrombocytopenic purpura. Gastroenterol Res Pract. 2017;2017:9529752. https:\/\/doi.org\/10.1155\/2017\/9529752.","journal-title":"Gastroenterol Res Pract"},{"issue":"5","key":"1528_CR3","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1111\/bjh.14414","volume":"175","author":"J Stentoft","year":"2016","unstructured":"Stentoft J. ITP: from idiopathic purpura to immune thrombocytopenia and back. Br J Haematol. 2016;175(5):755\u20136. https:\/\/doi.org\/10.1111\/bjh.14414.","journal-title":"Br J Haematol"},{"key":"1528_CR4","doi-asserted-by":"publisher","first-page":"273","DOI":"10.2147\/TCRM.S251672","volume":"18","author":"G Tsykunova","year":"2022","unstructured":"Tsykunova G, Ghanima W. Avatrombopag for the treatment of adult patients with chronic immune thrombocytopenia (cITP): focus on patient selection and perspectives. Ther Clin Risk Manag. 2022;18:273\u201386. https:\/\/doi.org\/10.2147\/TCRM.S251672.","journal-title":"Ther Clin Risk Manag"},{"issue":"7","key":"1528_CR5","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000032947","volume":"102","author":"JS Ruan","year":"2023","unstructured":"Ruan JS, Sun RJ, Wang JP, Sui XH, Qu HT, Yuan D, et al. Gene mutations in the PI3K\/Akt signaling pathway were related to immune thrombocytopenia pathogenesis. Medicine (Baltimore). 2023;102(7):e32947. https:\/\/doi.org\/10.1097\/MD.0000000000032947.","journal-title":"Medicine (Baltimore)"},{"key":"1528_CR6","unstructured":"Promacta\u00ae (eltrombopag) tablets for oral use. Initial U.S. approval: 2008. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2008\/022291lbl.pdf. Accessed 30 Jan 2026."},{"issue":"22","key":"1528_CR7","doi-asserted-by":"publisher","first-page":"2237","DOI":"10.1056\/NEJMoa073275","volume":"357","author":"JB Bussel","year":"2007","unstructured":"Bussel JB, Cheng G, Saleh MN, Psaila B, Kovaleva L, Meddeb B, et al. Eltrombopag for the treatment of chronic idiopathic thrombocytopenic purpura. N Engl J Med. 2007;357(22):2237\u201347. https:\/\/doi.org\/10.1056\/NEJMoa073275.","journal-title":"N Engl J Med"},{"issue":"22","key":"1528_CR8","doi-asserted-by":"publisher","first-page":"2227","DOI":"10.1056\/NEJMoa073255","volume":"357","author":"JG McHutchison","year":"2007","unstructured":"McHutchison JG, Dusheiko G, Shiffman ML, Rodriguez-Torres M, Sigal S, Bourliere M, et al. Eltrombopag for thrombocytopenia in patients with cirrhosis associated with hepatitis C. N Engl J Med. 2007;357(22):2227\u201336. https:\/\/doi.org\/10.1056\/NEJMoa073255.","journal-title":"N Engl J Med"},{"issue":"3","key":"1528_CR9","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1111\/bjh.18081","volume":"197","author":"H Al-Samkari","year":"2022","unstructured":"Al-Samkari H, Jiang D, Gernsheimer T, Liebman H, Lee S, Wojdyla M, et al. Adults with immune thrombocytopenia who switched to avatrombopag following prior treatment with eltrombopag or romiplostim: a multicentre US study. Br J Haematol. 2022;197(3):359\u201366. https:\/\/doi.org\/10.1111\/bjh.18081.","journal-title":"Br J Haematol"},{"issue":"2","key":"1528_CR10","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1002\/ajh.25348","volume":"94","author":"A Khelif","year":"2019","unstructured":"Khelif A, Saleh MN, Salama A, Portella M, Duh MS, Ivanova J, et al. Changes in health-related quality of life with long-term eltrombopag treatment in adults with persistent\/chronic immune thrombocytopenia: findings from the EXTEND study. Am J Hematol. 2019;94(2):200\u20138. https:\/\/doi.org\/10.1002\/ajh.25348.","journal-title":"Am J Hematol"},{"issue":"10","key":"1528_CR11","doi-asserted-by":"publisher","first-page":"864","DOI":"10.1016\/j.dld.2015.06.006","volume":"47","author":"S Bruno","year":"2015","unstructured":"Bruno S, Sewpaul P, Russo ML, Boccaccio V, Almasio PL, Giannini EG. 12 weeks of interferon-based therapy is feasible in patients with hepatitis C-related cirrhosis and thrombocytopenia: a post hoc analysis of eltrombopag studies. Dig Liver Dis. 2015;47(10):864\u20138. https:\/\/doi.org\/10.1016\/j.dld.2015.06.006.","journal-title":"Dig Liver Dis"},{"issue":"12","key":"1528_CR12","doi-asserted-by":"publisher","first-page":"1342","DOI":"10.1007\/s00535-012-0600-5","volume":"47","author":"T Kawaguchi","year":"2012","unstructured":"Kawaguchi T, Komori A, Seike M, Fujiyama S, Watanabe H, Tanaka M, et al. Efficacy and safety of eltrombopag in Japanese patients with chronic liver disease and thrombocytopenia: a randomized, open-label, phase II study. J Gastroenterol. 2012;47(12):1342\u201351. https:\/\/doi.org\/10.1007\/s00535-012-0600-5.","journal-title":"J Gastroenterol"},{"issue":"1","key":"1528_CR13","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1002\/ajh.27131","volume":"99","author":"N Cooper","year":"2024","unstructured":"Cooper N, Ghanima W, Vianelli N, Valc\u00e1rcel D, Yava\u015fo\u011flu \u0130, Melikyan A, et al. Sustained response off-treatment in eltrombopag-treated adult patients with ITP who are refractory or relapsed after first-line steroids: primary, final, and ad-hoc analyses of the phase II TAPER trial. Am J Hematol. 2024;99(1):57\u201367. https:\/\/doi.org\/10.1002\/ajh.27131.","journal-title":"Am J Hematol"},{"issue":"4","key":"1528_CR14","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1007\/s12185-017-2275-4","volume":"106","author":"TJ Gonz\u00e1lez-L\u00f3pez","year":"2017","unstructured":"Gonz\u00e1lez-L\u00f3pez TJ, Fern\u00e1ndez-Fuertes F, Hern\u00e1ndez-Rivas JA, S\u00e1nchez-Gonz\u00e1lez B, Mart\u00ednez-Robles V, Alvarez-Rom\u00e1n MT, et al. Efficacy and safety of eltrombopag in persistent and newly diagnosed ITP in clinical practice. Int J Hematol. 2017;106(4):508\u201316. https:\/\/doi.org\/10.1007\/s12185-017-2275-4.","journal-title":"Int J Hematol"},{"issue":"2","key":"1528_CR15","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1053\/j.gastro.2013.10.012","volume":"146","author":"NH Afdhal","year":"2014","unstructured":"Afdhal NH, Dusheiko GM, Giannini EG, Chen PJ, Han KH, Mohsin A, et al. Eltrombopag increases platelet numbers in thrombocytopenic patients with HCV infection and cirrhosis, allowing for effective antiviral therapy. Gastroenterology. 2014;146(2):442-52.e1. https:\/\/doi.org\/10.1053\/j.gastro.2013.10.012.","journal-title":"Gastroenterology"},{"issue":"11","key":"1528_CR16","doi-asserted-by":"publisher","first-page":"1260","DOI":"10.1002\/cpdd.1453","volume":"13","author":"J Wang","year":"2024","unstructured":"Wang J, Zhao Z, Tao Y, Lan Y. Bioequivalence and food effect assessment of eltrombopag olamine tablets in healthy Chinese subjects: an open, randomized, single\u2010dose, and two\u2010period crossover study. Clin Pharmacol Drug Dev. 2024;13(11):1260\u20136. https:\/\/doi.org\/10.1002\/cpdd.1453.","journal-title":"Clin Pharmacol Drug Dev"},{"issue":"5","key":"1528_CR17","doi-asserted-by":"publisher","first-page":"567","DOI":"10.2165\/00003495-200969050-00005","volume":"69","author":"KP Garnock-Jones","year":"2009","unstructured":"Garnock-Jones KP, Keam SJ. Eltrombopag. Drugs. 2009;69(5):567\u201376. https:\/\/doi.org\/10.2165\/00003495-200969050-00005.","journal-title":"Drugs"},{"issue":"4","key":"1528_CR18","doi-asserted-by":"publisher","first-page":"764","DOI":"10.1016\/j.clinthera.2009.04.010","volume":"31","author":"DD Williams","year":"2009","unstructured":"Williams DD, Peng B, Bailey CK, Wire MB, Deng Y, Park JW, et al. Effects of food and antacids on the pharmacokinetics of eltrombopag in healthy adult subjects: two single-dose, open-label, randomized-sequence, crossover studies. Clin Ther. 2009;31(4):764\u201376. https:\/\/doi.org\/10.1016\/j.clinthera.2009.04.010.","journal-title":"Clin Ther"},{"key":"1528_CR19","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2022.1012294","volume":"13","author":"X Qu","year":"2022","unstructured":"Qu X, Deng Q, Li Y, Li P, Liu G, Wang Y, et al. Pharmacokinetics and safety of the two oral cefaclor formulations in healthy chinese subjects in the fasting and postprandial states. Front Pharmacol. 2022;13:1012294.10.3389\/fphar.2022.1012294.","journal-title":"Front Pharmacol"},{"key":"1528_CR20","unstructured":"National Cancer Institute. Common Terminology Criteria for Adverse Events (CTCAE). Version 5.0. 2017. Available from: https:\/\/ctep.cancer.gov\/protocoldevelopment\/electronic_applications\/ctc.htm. Accessed 9 Jan 2025."},{"issue":"17","key":"1528_CR21","doi-asserted-by":"publisher","first-page":"1923","DOI":"10.1182\/blood-2016-10-740241","volume":"130","author":"E Vlachodimitropoulou","year":"2017","unstructured":"Vlachodimitropoulou E, Chen YL, Garbowski M, Koonyosying P, Psaila B, Sola-Visner M, et al. Eltrombopag: a powerful chelator of cellular or extracellular iron(III) alone or combined with a second chelator. Blood. 2017;130(17):1923\u201333. https:\/\/doi.org\/10.1182\/blood-2016-10-740241.","journal-title":"Blood"},{"issue":"4","key":"1528_CR22","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1016\/j.ipha.2023.04.003","volume":"1","author":"L Li","year":"2023","unstructured":"Li L, Wang W, Xue X, Miao W, Liu X, Cheng X, et al. Current status and cost burden of non-first-line treatment in ITP: a multicenter study based on real-world data in China. Intell Pharm. 2023;1(4):274\u20139. https:\/\/doi.org\/10.1016\/j.ipha.2023.04.003.","journal-title":"Intell Pharm"}],"updated-by":[{"DOI":"10.1007\/s40261-026-01542-2","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T00:00:00Z","timestamp":1777507200000}}],"container-title":["Clinical Drug Investigation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40261-026-01528-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40261-026-01528-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40261-026-01528-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T10:55:49Z","timestamp":1777546549000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40261-026-01528-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,7]]},"references-count":22,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["1528"],"URL":"https:\/\/doi.org\/10.1007\/s40261-026-01528-0","relation":{},"ISSN":["1173-2563","1179-1918"],"issn-type":[{"value":"1173-2563","type":"print"},{"value":"1179-1918","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,7]]},"assertion":[{"value":"18 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 April 2026","order":5,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":6,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1007\/s40261-026-01542-2","URL":"https:\/\/doi.org\/10.1007\/s40261-026-01542-2","order":8,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All data related to this study were interpreted by the trial staff with complete independence from the\u00a0sponsor. Qin Ren, Yanli Wang, Yannan Zhou, Zhengzhi Liu, Yang Cheng, Qiaohuan Deng, Yingzi Cui, and Haimiao Yang are employees of the Affiliated Hospital of Changchun University of Chinese Medicine and Keyi Wu is an employee of Chia Tai Tianqing Pharmaceutical Group Co., Ltd. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in the subject matter or materials discussed in the article apart from those disclosed.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This study was approved by the Ethics Committee of the Affiliated Hospital of Changchun University of Chinese Medicine (date: 2023.02.10, No. CCZYFYLL2023). All procedures followed were in accordance with the ethical standards set out in the Declaration of Helsinki.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Written informed consent was obtained from all participants included in the study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"We confirm that the figures and tables in this article are original and have not been published before. The data that support the findings of this study are available from the corresponding author upon reasonable request but remain subject to all applicable legal requirements to protect the confidentiality of the study subjects\u2019 personal information.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and material"}},{"value":"Not applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"HY and YC contributed to the conception and design of the study. QR, YW, YZ, YC, and ZL were responsible for material preparation and data collection. KW and QD drafted the initial version of the manuscript. YC and HY critically reviewed and approved the final manuscript. All authors read and approved the final version and agree to be accountable for all aspects of the work.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author contributions"}}]}}